Back to News
Market Impact: 0.2
Adlai Nortye Receives FDA Clearance For AN4035 Phase I Trial
Source: Nasdaq
Healthcare & BiotechProduct Launches
Adlai Nortye Group dosed the first patient in Australia in its global Phase I trial of AN4035. The investigational first-in-class antibody-drug conjugate targets CEACAM5 and delivers a pan-RAS(ON) inhibitor payload, marking an early clinical-development milestone with limited near-term financial visibility.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ANL0.65
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Oncologists Cheer Melanoma Data
- Scalpers offer Apple iPhone Duo buyers hundreds extra outside Beijing launch
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Run Cost-Controlled Financial Research in AllMind Agent Studio